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setting: Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) act on the 
same receptor, activating different signal transduction pathways. The role of LH or hCG 
addition to follicle-stimulating hormone (FSH) as well as menopausal gonadotropins 
(human menopausal gonadotropin; hMG) in controlled ovarian stimulation (COS) is 
debated.
Objective: To compare FSH +  LH, or FSH +  hCG or hMG vs. FSH alone on COS 
outcomes.
Design: A meta-analysis according to PRISMA statement and Cochrane Collaboration 
was performed, including prospective, controlled clinical trials published until July 2016, 
enrolling women treated with FSH alone or combined with other gonadotropins. Trials 
enrolling women with polycystic ovarian syndrome were excluded (PROSPERO registra-
tion no. CRD42016048404).
results: Considering 70 studies, the administration of FSH alone resulted in higher 
number of oocytes retrieved than FSH + LH or hMG. The MII oocytes number did not 
change when FSH alone was compared to FSH + LH, FSH + hCG, or hMG. Embryo 
number and implantation rate were higher when hMG was used instead of FSH alone. 
Pregnancy rate was significantly higher in FSH + LH-treated group vs. others. Only 12 
studies reported live birth rate, not providing protocol-dependent differences. Patients’ 
stratification by GnRH agonist/antagonist identified patient subgroups benefiting from 
specific drug combinations.
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conclusion: In COS, FSH alone results in higher oocyte number. HMG improves the 
collection of mature oocytes, embryos, and increases implantation rate. On the other 
hand, LH addition leads to higher pregnancy rate. This study supports the concept of a 
different clinical action of gonadotropins in COS, reflecting previous in vitro data.
Keywords: follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotropin, human menopausal 
gonadotropin, pregnancy rate, assisted reproductive technology, controlled ovarian stimulation
inTrODUcTiOn
Luteinizing hormone (LH) and human chorionic gonadotropin 
(hCG) are heterodimeric glycoprotein hormones, acting on 
the same receptor (LHCGR) (1). These gonadotropins were 
considered equivalent at the molecular level for long time, until 
the demonstration of specific intracellular-mediated signaling 
(2). In vitro models of human granulosa cells demonstrated 
that hCG is more potent than LH in inducing cyclic adenosine 
monophosphate production (cAMP) production (2), while the 
latter leads to preferential ERK1/2 and AKT pathways activa-
tion (2). Thus, although LH and hCG activate different kinetics 
(2, 3), whether and how they differently influence in vivo response 
remains unclear (4).
In humans, follicle-stimulating hormone (FSH) and LH act 
in concert to stimulate folliculogenesis and ovulation. Therefore, 
these gonadotropins are used in the controlled ovarian stimula-
tion (COS) in order to produce relatively high oocyte number 
to be used fresh or after cryopreservation (5) to obtain pregnan-
cies. The physician identifies the presumably most appropriate 
regimen, in terms of gonadotropin-releasing hormone (GnRH) 
analog protocol, FSH formulation, starting FSH dose, and 
combination of different gonadotropins, following the evaluation 
of demographic, anthropometric, and ovarian reserve profiles 
(6–8). Generally, FSH is selected as standard treatment, and 
hCG or LH may be added. The knowledge of human physiology 
provides a rationale for LH activity supplementation during COS. 
Although in vitro and animal models provided the evidences of 
hormone-specific actions, the choice of the optimal gonadotropin 
combination to be used in COS is not well standardized and 
remains entrusted to clinician’s decision. Especially, the preg-
nancy hormone hCG is generally used to obtain LH-like activity 
and support of multi-follicle growth since decades (9). With this 
in mind, human menopausal gonadotropin (hMG) is commonly 
used as preparation with LH-like activity, due to the presence of 
LH and/or hCG molecules. hMG alone and hCG/LH + FSH were 
repeatedly proposed (10, 11) but some unfavorable results, in par-
ticular in terms of number of oocytes retrieved (12, 13), provided 
concerns about the usefulness of addition of “LH activity.”
Currently, the gonadotropin market offers a wide choice, 
including urinary and recombinant preparations of FSH, LH, 
hCG, and hMG alone or in various combinations, recently further 
enriched by biosimilars. This palette of competitor drugs, regis-
tered for the same indication but biochemically and physiologi-
cally different, introduced the concept of “personalized” assisted 
reproductive technology (ART) schemes, which is very attractive 
for patients and doctors but not supported by solid evidence and 
largely industry-promoted. These gonadotropins show different 
kinetics in in vitro models, but no clear in vivo differences in COS 
are available so far. Most studies have been tried to answer the 
question of what is the best gonadotropin combinations, although 
inconclusive results were achieved, not sufficient to guide a really 
evidence-based, personalized choice in ART. Indeed, no power-
ful, properly designed, controlled prospective clinical trials are 
available to support the rationale of any COS scheme so far. As 
a matter of fact, the design of randomized clinical trials is chal-
lenging in this setting, due to the peculiar emotional situation 
and heterogeneity of the infertile population together with the 
time and costs required. Thus, 64 meta-analyses have been 
published to compare different ART approaches and outcomes 
(Table 1). However, each review is focused on a specific single 
comparison (e.g., hMG vs. FSH, GnRH agonist vs. antagonists, 
etc.) in a peculiar clinical setting. In particular, 25 systematic 
reviews compared the efficacy of different GnRH analogs, 17 
compared urinary and recombinant FSH preparations, and only 
6 evaluated the efficacy of LH supplementation to FSH (Table 1). 
None of these comparisons provided a comprehensive analysis 
of entire process, from oocyte recruitment to live birth rate, and 
their conclusions are rarely translated in clinical practice. In fact, 
no accepted guideline exists in this field of medicine in which 
registered indications and reimbursability of gonadotropins by 
the national health care systems are guided by costs rather than 
scientific evidence/clinical outcome.
Having in mind physiology and the different in vitro effects of 
LH and hCG, in this work, we addressed the question whether 
LH, LH-like activity, and hCG could have different results on 
COS outcomes. To this purpose, we evaluated the efficacy of LH 
or hCG plus FSH or hMG alone, compared to what is considered 
the standard care for COS, i.e., the use of FSH alone, using a 
meta-analytic approach. This is the first meta-analysis in which 
all gonadotropin combinations are considered. Moreover, a 
full-spectrum evaluation of all ART endpoints is provided, to 
recognize when and how LH, LH-activity, and hCG influence 
ART outcomes.
MaTerials anD MeThODs
We performed a meta-analysis according to the Cochrane 
Collaboration and PRISMA statement. The meta-analysis was 
accepted in the International Prospective Register of Systematic 
Reviews (PROSPERO; registration n. CRD42016048404) prior to 
commencing the study, ensuring transparency and originality of 
the review process.
Data sources and searches
We conducted a comprehensive literature search for English-
language articles in MEDLINE (PubMed), EMBASE, Cochrane 
Library, SCOPUS, and UpToDate, published until July 2016. 
TaBle 1 | Previous meta-analysis characteristics.
First author Journal Year comparison end-points number of studies
Daya Fertil Steril 1995 U-follicle-stimulating hormone (FSH) vs. r-FSH Pregnancy rate 8
Daya Cochrane Database Syst Rev 1996 U-FSH vs. r-FSH Withdrawan
Daya Hum Reprod 1999 U-FSH vs. r-FSH Oocytes retrieved 12
Nugent Cochrane Database Syst Rev 2000 Different u-FSH in polycystic ovarian syndrome (PCOS) Pregnancy rate 23
Daya Cochrane Database Syst Rev 2000 U-FSH vs. r-FSH Pregnancy rate 18
van Wely Fertil Steril 2003 Human menopausal gonadotropin (hMG) vs. r-FSH Pregnancy rate 6
Al-Inany Hum Reprod 2003 U-FSH vs. r-FSH Oocytes retrieved 20
Albuquerque Cochrane Database Syst Rev 2005 Depot gonadotropin-releasing hormone (GnRH)  
agonist vs. daily GnRH agonist
Pregnancy rate 6
Pandian Cochrane Database Syst Rev 2005 In vitro fertilization (IVF) vs. intrauterine insemination (IUI) Pregnancy rate 10
Sallam Cochrane Database Syst Rev 2006 GnRH agonist timing in endometriosis Pregnancy rate 3
Griesinger Reprod Biomed Online 2006 GnRH agonist vs. GnRH antagonist in PCOS Oocytes retrieved 13
Franco Reprod Biomed Online 2006 GnRH agonist vs. GnRH antagonist in PCOS Oocytes retrieved 6
Sunkara Reprod Biomed Online 2007 GnRH agonist vs. GnRH antagonist Oocytes retrieved 9
Mochtar Cochrane Database Syst Rev 2007 R-luteinizing hormone (LH) plus r-FSH vs. r-FSH Live birth rate 14
Pandian Cochrane Database Syst Rev 2007 Different GnRH analog protocols Live birth rate 9
Daya Cochrane Database Syst Rev 2007 U-FSH vs. r-FSH Withdrawan
Kolibianakis Hum Reprod Update 2007 R-LH plus r-FSH vs. r-FSH in GnRH antagonist Live birth rate 5
Baruffi Reprod Biomed Online 2007 R-LH plus r-FSH vs. r-FSH in GnRH antagonist Oocytes retrieved 5
Al-Inany Reprod Biomed Online 2008 hMG vs. r-FSH Live birth rate 10
Coomarasamy Hum Reprod 2008 U-FSH vs. r-FSH Live birth rate 7
Al-Inany Reprod Biomed Online 2008 hMG vs. r-FSH Live birth rate 5
Al-Inany Gynecol Endocinol 2009 hMG vs. r-FSH Pregnancy rate 6
Jee Gynecol Obstet Invest 2010 hMG vs. r-FSH Pregnancy rate 10
Lehert Reprod Biol Endocrinol 2010 hMG vs. r-FSH Oocytes retrieved 16
Pandian Cochrane Database Syst Rev 2010 GnRH agonist vs. GnRH antagonist Live birth rate 15
Pandian Cochrane Database Syst Rev 2010 Different GnRH analog protocols Live birth rate 10
Sterrenburg Hum Reprod Update 2011 Different r-FSH doses Pregnancy rate 10
Al-Inany Cochrane Database Syst Rev 2011 GnRH agonist vs. GnRH antagonist Live birth rate 45
Youssef Cochrane Database Syst Rev 2011 GnRH agonist vs. hCG for trigger Live birth rate 11
van Wely Cochrane Database Syst Rev 2011 hMG vs. r-FSH Live birth rate 42
Youssef Cochrane Database Syst Rev 2011 U-hCG vs. r-hCG Live birth rate 14
Siristatidis Cochrane Database Syst Rev 2011 Different GnRH agonist protocols Pregnancy rate 29
Maheshwari Cochrane Database Syst Rev 2011 Short vs. ultra-short GnRH agonist protocols Pregnancy rate 29
Pundir Hum Reprod 2011 GnRH agonist vs. GnRH antagonist Oocytes retrieved 14
Bodri Fertil Steril 2011 GnRH agonist vs. GnRH antagonist Pregnancy rate 8
van Wely Hum Reprod Update 2012 hMG vs. r-FSH Live birth rate 42
Hill Fertil Steril 2012 R-LH plus r-FSH vs. r-FSH in GnRH antagonist Pregnancy rate 7
Konig Fertil Steril 2012 R-LH plus r-FSH vs. r-FSH in GnRH antagonist in  
women older than 35 years
Pregnancy rate 9
Mahmoud Youssef Fertil Steril 2012 Long acting FSH vs. r-FSH Pregnancy rate 4
Pandian Cochrane Database Syst Rev 2012 IVF vs. IUI Pregnancy rate 6
Gibreel Cochrane Database Syst Rev 2012 Gonadotropins vs. clomiphene citrate Live birth rate 14
Pouwer Cochrane Database Syst Rev 2012 Long acting FSH vs. r-FSH Live birth rate 4
Pundir Reprod Biomed Online 2012 GnRH agonist vs. GnRH antagonist in PCOS OHSS rate 9
Albuquerque Cochrane Database Syst Rev 2013 Depot GnRH agonist vs. daily GnRH agonist Pregnancy rate 16
Matsaseng Gynecol Obstet Invest 2013 Mild ovarian stimulations vs. traditional IVF Pregnancy rate 5
Xiao Fertil Steril 2013 GnRH agonist vs. GnRH antagonist Pregnancy rate 12
Fan Gynecol Endocinol 2013 rLH supplementation in poor responders Pregnancy rate 3
Xiao Gynecol Endocinol 2013 GnRH agonist vs. GnRH antagonist Oocytes retrieved 7
Youssef Cochrane Database Syst Rev 2014 GnRH agonist vs. hCG for trigger Live birth rate 17
Xiao PlosONE 2014 GnRH agonist vs. GnRH antagonist Oocytes retrieved 23
Chen Gynecol Endocinol 2014 Timing of hCG administration Oocytes retrieved 7
Lin PlosONE 2014 GnRH agonist vs. GnRH antagonist Pregnancy rate 9
Hu J Int Med Res 2014 LH priming vs. FSH alone Estradiol serum levels 3
Song Gynecol Endocinol 2014 GnRH agonist vs. letrozole Pregnancy rate 3
Siristatidis Cochrane Database Syst Rev 2015 different GnRH agonist protocols Pregnancy rate 37
Weiss Cochrane Database Syst Rev 2015 U-FSH vs. r-FSH in PCOS Live birth rate 14
Nugent Cochrane Database Syst Rev 2015 Different u-FSH in PCOS Withdrawan
Nahuis Cochrane Database Syst Rev 2015 U-FSH vs. r-FSH in PCOS Withdrawan
Pandian Cochrane Database Syst Rev 2015 IVF vs. IUI Pregnancy rate 8
Pouwer Cochrane Database Syst Rev 2015 Long acting FSH vs. r-FSH Live birth rate 6
Youssef J Adv Res 2015 GnRH agonist vs. hCG for trigger Pregnancy rate 19
(Continued)
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First author Journal Year comparison end-points number of studies
Fensore J Ovar Res 2015 Long acting FSH vs. r-FSH Oocytes retrieved 7
Al-Inany Cochrane Database Syst Rev 2016 GnRH agonist vs. GnRH antagonist Live birth rate 63
Youssef Cochrane Database Syst Rev 2016 U-hCG vs. r-hCG Live birth rate 18
TaBle 1 | continued
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Search key words were as follows: controlled ovarian stimulation 
(COS), controlled ovarian hyperstimulation (COH), ART, in vitro 
fertilization (IVF), intracytoplasmatic sperm injection  (ICSI), 
luteinizing hormone (LH), follicle stimulating hormone (FSH), 
human menopausal gonadotropin (hMG), hCG, follitropin, 
oocytes retrieved, and pregnancy. The Boolean functions AND 
and OR were used to combine key words listed above.
study selection and inclusion criteria
Types of Studies
The inclusion criteria, established before the literature search, 
were
• Prospective, longitudinal, and controlled clinical trials;
• Enrollment of women without limits of age;
• Treatment with LH or hCG or hMG during the follicular 
development phase.
Retrospective studies were not included. Similarly, trials 
enrolling women with polycystic ovarian syndrome (PCOS) were 
excluded, due to peculiar endocrine features of these patients. 
The ART methodology chosen was not an inclusion or exclusion 
criterion. However, each outcome was further evaluated consid-
ering the studies on the basis of the ART protocol used. Finally, 
randomization was not considered a strict inclusion criterion, 
thus randomized, semirandomized, and non-randomized clini-
cal trials were reviewed. Therefore, all available controlled studies 
were considered increasing sample size, in spite of the wide range 
of clinical protocols available.
Type of Participants
Women undergoing COS for ART were considered. No inclusion 
criteria were applied for the male partner of the infertile couple.
Type of Interventions
All ART stimulation protocols were considered and studies 
included provided the comparison between LH, hCG, or hMG in 
the follicular phase with FSH.
Data collection Process and Quality
Two authors (Santi Daniele and Casarini Livio) extracted the 
abstracts from all studies found through literature search until 
July 2016. All abstracts were evaluated for inclusion criteria, and 
data were extracted from each study considered eligible, with 
regard to study design, year of publication, number of included/
excluded subjects, number of dropped-out patients, and the use 
of intention to treat or per protocol analysis.
The quality of trials was assessed using the parameters pro-
posed by Jadad et al. (14) and Table 2 summarizes the features of 
the selected studies.
Although studies considered in the meta-analysis used differ-
ent endpoints, we performed an overall meta-analysis consider-
ing all studies evaluating at least pregnancy rate or number of 
oocytes retrieved.
The investigators (DS and LC), using Cochrane risk-of-bias 
algorithm, independently assessed the risk-of-bias for all trials. 
The following quality criteria and methodological details were 
evaluated for each trial included in the meta-analysis: (i) method 
of randomization, even if the randomization was not an inclusion 
criterion; (ii) concealment of allocation; (iii) presence or absence 
of blinding to treatment allocation; (iv) duration and type of treat-
ment and follow-up phases; (v) number of participants recruited, 
analyzed, or lost to follow-up; (vi) timing of trial; (vii) whether 
an intention to treat analysis was done; (viii) whether a power 
calculation was done; (ix) source of funding; and (x) criteria for 
including participants and assessing outcomes.
summary Measures
The primary outcome was the number of oocytes retrieved, 
evaluated as mean difference between the two types of treatment 
compared. The choice of the primary endpoint derived from the 
consideration that the number of oocytes retrieved is the unique 
endpoint available in almost all trials in ART setting. Moreover, 
our meta-analysis aimed at comparing the efficacy in  vivo of 
gonadotropin combinations, and the number of oocytes retrieved 
best described pathophysiologically the first step influenced by 
gonadotropin administration, i.e., follicular and oocyte develop-
ment. The oocytes number remains the first measurable and 
reproducible parameter to describe gonadotropin action in vivo.
In clinical practice, the main ART outcome remains live birth 
rate. However, this parameter was not considered as primary 
endpoint in our meta-analysis, since it is influenced by a large 
number of unquantifiable biases and variables. Indeed, the vast 
majority of clinical trials dedicated to ART outcome do not report 
this parameter. In fact, the step following oocyte collection, i.e., 
embryo development, is strongly influenced by another impor-
tant confounding factor, i.e., sperm quality, which is usually (and 
unexplainably) disregarded. Further, implantation rate follows 
embryo development and it is, in turn, affected by other factors, 
such as the endometrium thickness and activity, which are usu-
ally not controlled for. Continuing until pregnancy and live birth 
rate, each step is influenced by a number of factors, not immedi-
ately dependent on gonadotropins. Accordingly, the relationship 
between live birth rate and oocytes retrieved is suggested in the 
literature (15), but not universally accepted (16, 17). For these 
reasons, it is not possible to identify a unique endpoint to evaluate 
COS outcomes. Thus, we considered each available COS outcome 
after the number of oocytes retrieved as secondary endpoints, 
i.e., MII oocytes number, embryos, implantation rate, pregnancy 
TaBle 2 | characteristics of included studies.
control 
group
study 
group
authors Year Protocol used arT number Mean 
age 
(years)
Drug 1 name startig 
doe  
(iU/daily)
Drug 2 name startig 
doe  
(iU/daily)
Drop 
out
numr Mean 
age 
(years)
Drug 1 name startig 
doe  
(iU/daily)
Drug 2 name startig 
doe  
(iU/daily)
Drop 
out
Gerli 1993 Gonadotropin- 
releasing 
hormone (GnRH) 
agonist
In vitro 
fertilization 
(IVF)
17 30.9 FSH Metrodin 225 2 15 31.4 hMG Pergonal 225 1
Daya 1995 GnRH agonist IVF 115 33.5 FSH Metrodin 150 117 33.2 hMG Pergonal 150
Westergaard 1996 GnRH agonist IVF 104 31.0 FSH Fertinorm 225 114 32.0 hMG Pergonal 225
Jansen 1998 None IVF 47 32.0 FSH Puregon 150 32 31.1 hMG Humegon 225
Filicori 1999 GnRH agonist IVF 10 32.0 FSH Metrodin 300 0 10 33.0 FSH Metrodin 300 hCG Profasi 50 0
Sills 1999 GnRH agonist IVF 17 35.4 FSH Fertinex 14 36.7 FSH Fertinex LH Lhadi 75
Balasch 2001 GnRH agonist IVF 14 33.6 FSH Gonal F 150 1 16 34.8 FSH Gonal F 150 LH Luveris 75 1
De Placido 2001 GnRH agonist IVF 40 30.1 FSH Gonal F 300 0 20 31.6 FSH Gonal F 150 hMG Menogon 150 0
Filicori 2001 GnRH agonist IVF 25 32.0 FSH Metrodin 150 0 25 33.0 hMG Menogon 150 0
Gordon 2001 GnRH agonist IVF 69 33.5 FSH Puregon 225 12 59 33.5 hMG Humegon 75 6
Ng 2001 GnRH agonist IVF 20 33.5 FSH Gonal F 300 20 32.0 hMG Pergonal 300
Strehler 2001 GnRH antagonist IVF 248 32.3 FSH Gonal F 300 259 31.8 hMG Menogon 300
Westergaard 2001 GnRH agonist IVF 190 FSH Gonal F 225 2 189 hMG Menogon 225 3
Filicori 2002 GnRH agonist IVF 30 31.9 FSH Metrodin 150 90 32.7 FSH Metrodin 150 LH Menogon 75
Ismail 2002 GnRH agonist IVF 75 33.2 FSH Fostimon 150 78 34.3 hMG Menogon 150
Lisi 2002 GnRH agonist IVF 331 34.7 FSH Gonal F 150 122 34.8 FSH Gonal F 150 LH Luveris 75
Filicori a 2003 GnRH agonist Intrauterine 
insemination 
(IUI)
25 31.9 FSH Gonal F 150 25 32.6 hMG Menogon 150
Filicori b 2003 GnRH agonist IVF 50 25.9 FSH Gonal F 150 14 50 27 hMG Menopur 150 12
Ku 2003 GnRH agonist IVF 19 34.6 FSH Metrodin 300 26 33.0 FSH Metrodin 300 hMG Pergonal 75
Marrs 2003 GnRH agonist IVF 219 31.9 FSH Gonal F 225 212 32.4 FSH Gonal F 225 LH Luveris 150
Acevedo 2004 GnRH antagonist IVF 20 23.0 FSH Gonal F 225 22 26.0 FSH Gonal F 225 LH Luveris 75
Cédrin-Durnerin 2004 GnRH antagonist IVF 96 31.7 FSH Gonal F 150 2 107 31.4 FSH Gonal F 150 LH Luveris 75 0
De Placido 2004 GnRH agonist IVF 46 30.4 FSH Gonal F 150 46 30.0 FSH Gonal F 150 LH Luveris 75
Ferraretti 2004 GnRH agonist IVF 104 31.7 FSH Gonal F 225 2 54 31.5 FSH Gonal F 225 LH Luveris 75 4
Ferraretti 2004 GnRH agonist IVF 104 31.7 FSH Gonal F 225 2 22 32.0 FSH Gonal F 225 hMG Menogon
Humaidan 2004 GnRH agonist IVF 115 30.5 FSH Puregon 150 116 30.8 FSH Puregon 150 LH Luveris
Loutradis 2004 GnRH agonist IVF 106 37.3 FSH 200 98 38.1 FSH 200 hMG
De Placido 2005 GnRH agonist IVF 58 30.4 FSH Gonal F 225 57 31.5 FSH Gonal F 225 LH Luveris 150
Drakakis 2005 GnRH agonist IVF 22 33.0 FSH Puregon 200 24 32.4 FSH Puregon 200 hMG Menogon 75
Filicori 2005 GnRH agonist IVF 24 33.4 FSH Puregon 225 24 33.8 FSH Puregon 225 hCG Gonasi 200
Gómez-Palomares 2005 GnRH antagonist IVF 58 39.0 FSH Gonal F 225 hMG HMG-
Lepori
75 4 36 38.8 FSH Gonal F 300 LH Luveris 75 2
Griesinger 2005 GnRH antagonist IVF 65 30.5 FSH Gonal F 150 11 62 30.3 FSH Gonal F 150 LH Luveris 75 6
Hugues 2005 None IVF 30 29.9 FSH Gonal F 150 0 117 29.3 FSH Gonal F 150 LH Luveris 150–300 1
Fabregues 2006 GnRH agonist IVF 60 38.2 FSH Gonal F 150 5 60 38.4 FSH Gonal F 150 LH Luveris 150 5
Levi-Setti 2006 GnRH antagonist IVF 20 32.3 FSH Gonal F 225 4 20 32.2 FSH Gonal F 150 LH Luveris 75 2
Tarlatzis 2006 GnRH agonist IVF 59 30.3 FSH Gonal F 150 2 55 30.5 FSH Gonal F 150 LH Luveris 75 0
Berkkanoglu 2007 GnRH agonist IVF 51 34.9 FSH Gonal F 600 46 36.3 FSH Gonal F 600 LH Luveris 75
Berkkanoglu 2007 GnRH agonist IVF 51 34.9 FSH Gonal F 600 48 35.2 FSH Gonal F 600 hCG Ovitrelle 75
Demirol 2007 None IUI 161 30.4 FSH Gonal F 150 0 80 30.8 hMG 150 0
Ziebe 2007 GnRH agonist IVF 368 FSH 225 363 hMG 225
Barrenetxea 2008 GnRH agonist IVF 42 41.8 FSH Gonal F 300 42 42.1 FSH Gonal F 300 LH Luveris 150
Bosch 2008 GnRH antagonist IVF 140 33.4 FSH Gonal F 225 20 140 33.2 hMG Menopur 225 23
Hompes 2008 GnRH antagonist IVF 317 32.0 FSH Gonal F 150 15 312 31.7 hMG Menopur 150 19
(Continued)
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control 
group
study 
group
authors Year Protocol used arT number Mean 
age 
(years)
Drug 1 name startig 
doe  
(iU/daily)
Drug 2 name startig 
doe  
(iU/daily)
Drop 
out
numr Mean 
age 
(years)
Drug 1 name startig 
doe  
(iU/daily)
Drug 2 name startig 
doe  
(iU/daily)
Drop 
out
Nyboeandersen 2008 GnRH agonist IVF 261 31.8 FSH Gonal F 150 0 265 31.7 FSH Gonal F 150 LH Luveris 75 0
Blockeel 2009 GnRH antagonist IVF 35 30.0 FSH Puregon 225 3 35 29.0 FSH Puregon 225 hCG Pregnyl 200 6
Check 2009 GnRH antagonist IVF 35 35.1 FSH 300 1 35 33.6 FSH 300 hCG 25 3
Drakakis 2009 GnRH agonist IVF 58 36.4 FSH Gonal F 200 rhCG 200 56 37.3 FSH Gonal F 200 LH
Matorras 2009 GnRH agonist IVF 68 36.7 FSH Gonal F 300 3 63 36.6 FSH Gonal F 300 LH Luveris 150 0
Melo 2010 GnRH agonist IVF 346 24.9 FSH Gonal F 225 333 23.9 hMG Menopur 225
Pacchiarotti 2010 GnRH antagonist IVF 60 hMG Menopur 225 2 62 FSH Pergoveris 225 LH Luveris 8
Bosch 2011 GnRH antagonist IVF 314 34.6 FSH Gonal F 225 50 311 34.7 FSH Gonal F 150 LH Luveris 75 56
Caserta 2011 GnRH agonist IVF 501 34.8 FSH Gonal F 150 498 34.3 FSH Gonal F 150 LH
Kokac 2011 GnRH agonist IUI 24 29.5 FSH Gonal F 75 25 28.8 hMG Merional 75
Pezzuto 2011 GnRH agonist IVF 40 34.0 FSH Puregon 225 40 35.0 FSH Puregon 225 LH Luveris 75
Sagnella 2011 IUI 262 35.4 FSH Gonal F 150 23 261 35.0 hMG Meropur 75–150 5
Barberi 2012 GnRH agonist IVF 11 32.3 FSH Gonal F 150 10 9 34.1 FSH Gonal F 150 LH Luveris 75 2
Devroy 2012 GnRH antagonist IVF 375 30.4 FSH Puregon 150 59 374 30.8 hMG Menopur 150 69
Lisi 2012 GnRH agonist IVF 75 32.8 FSH Gonal F 150 75 33.6 FSH Gonal F 150 LH 75
Madani 2012 GnRH antagonist IVF 26 39.2 FSH Gonal F 300 0 47 38.9 FSH Gonal F 300 hCG Pregnyl 200 0
Revelli 2012 GnRH antagonist IVF 266 39.2 FSH Gonal F 300 27 264 39.4 FSH Gonal F 150 LH Luveris 150 29
Thuesen 2012 GnRH agonist IVF 16 31.5 FSH Puregon 150 2 46 32.6 FSH Puregon 150 hCG Predalon 100 5
Ye 2012 GnRH agonist IVF 64 36.2 FSH Gonal F 225 63 36.2 hMG Menopur 225
Konig 2013 GnRH antagonist IVF 128 37.9 FSH Gonal F 225 17 125 38.0 FSH Gonal F 225 LH Luveris 150 14
Rashidi 2013 IUI 132 28.7 FSH Gonal F 75 3 127 29.1 hMG Menogon 75 1
Thuesen 2013 GnRH agonist IVF 16 32.3 FSH Puregon 150 0 46 32.3 FSH Puregon 150 hCG Predalon 100 0
Razi 2014 GnRH agonist IVF 20 31.3 FSH Gonal F 150 0 20 31.8 FSH Gonal F 150 LH Luveris 75 0
Behre 2015 GnRH agonist IVF 99 37.6 FSH Gonal F 300 1 103 37.4 FSH Gonal F 300 LH Luveris 150 2
Moro 2015 none IUI 289 37.9 hMG Meropur 150 5 290 38.4 FSH Gonal F 150 LH Luveris 150 13
Vuong 2015 GnRH antagonist IVF 120 38.0 FSH Gonal F 300 11 120 38.0 FSH Gonal F 300 LH Pergoveris 150 18
Yilmaz 2015 GnRH agonist IVF 87 29.0 FSH Puregon 50 30.3 FSH Puregon LH Luveris 75
Younis 2016 GnRH antagonist IVF 30 38.6 FSH Gonal F 300 6 32 38.9 FSH Gonal F 300 LH Luveris 150 5
TaBle 2 | continued
6
S
anti et al.
The G
onadotropin C
om
binations in A
R
T
Frontiers in Endocrinology | w
w
w
.frontiersin.org
June 2017 | Volum
e 8 | A
rticle 114
FigUre 1 | study flow chart.
TaBle 3 | number of studies evaluated in each comparison and in each subgroup analysis.
Fsh + lh vs. Fsh alone Fsh + hcg vs. Fsh alone hMg vs. Fsh alone
Overall analyses 34 9 29
subgroup analyses
GnRH antagonists 10 3 5
GnRH agonists 22 6 20
GnRH analogs missing data 2 0 4
In vitro fertilization/intracytoplasmatic sperm injection 33 9 26
Intrauterine insemination 1 0 3
ART schemes missing information 0 0 0
ART, assisted reproductive technology; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone.
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rate, and live birth rate. Moreover, FSH dosage used and the ratio 
FSH dosage/number of oocytes retrieved were evaluated in order 
to describe the amount of gonadotropin needed to obtain each 
oocyte.”
Data synthesis and analysis
The meta-analysis was conducted using the Review Manager 
(RevMan) software (Version 5.3.1 Copenhagen: The Nordic 
Cochrane Center, The Cochrane Collaboration, 2014). Data were 
combined using the fixed effect model and weighted mean dif-
ferences, and 95% confidence intervals were estimated for each 
endpoint. The random effect model was used when high hetero-
geneity resulted among studies, as evaluated by I2 statistics. Meta-
regression analyses were performed to evaluate the relationship 
between continuous variables.
Values of p < 0.05 were considered statistically significant.
risk-of-Bias across studies
Two authors (Santi Daniele and Casarini Livio) independently 
evaluated risk-of-bias. Although randomization is not a strict 
inclusion criterion, it was evaluated as source of biases following 
the suggestions provided by the Cochrane collaboration.
resUlTs
Of the 2,117 publications initially identified, 1,602 remained after 
duplicates removal. According to the strategy research, we identi-
fied 196 potentially relevant studies, based on the information 
given in the abstract. All trials were thoroughly appraised for eli-
gibility in the meta-analysis and methodological quality. Seventy 
studies were included in the final analysis (Table 2; Figure 1).
considerations on study Design
The mean age of all patients was 33.21 ± 3.43 years. Considering 
the wide heterogeneity in clinical trials included in the analysis, 
regarding inclusion criteria, FSH starting dose chosen and ART 
approaches, several subgroup analyses were performed (Table 3). 
In a subgroup analyses, studies were divided according to the 
GnRH analog used, agonist or antagonist, respectively. In sub-
group analyses, three studies were excluded considering that hMG 
was administered together with FSH (18–20). An insufficient 
number of studies were available on the comparison between FSH 
alone vs. FSH + hCG and between FSH + LH vs. FSH + hCG, 
limiting the possibility to subgroup studies. Finally, considering 
the whole group of studies included in the meta-analysis, the ART 
approaches chosen after COS were different, ranging from intrau-
terine insemination (IUI) to intracytoplasmatic sperm injection 
(ICSI). However, only four studies evaluated IUI (21–24), thus 
the vast majority of trials included in the analysis considered IVF/
ICSI. Moreover, of these four studies, three compared hMG to 
FSH alone (21–23) and one LH + FSH to FSH + hCG alone (24). 
Thus, a subgroup analysis, excluding studies performing IUI, was 
performed.
number of Oocytes retrieved
Twenty-nine studies evaluated the comparison of FSH alone vs. 
FSH + LH, for a total of 5,840 patients. Studies using FSH alone 
retrieved a significantly higher number of oocytes compared to 
FSH + LH treatment (p = 0.010) (Figure 2A; Table 4). However, 
different results were found depending on COS protocol. In 
FigUre 2 | continued
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particular, higher oocyte numbers were retrieved when FSH 
was administered alone in a GnRH agonist protocol (p = 0.010), 
while no differences were observed in GnRH antagonist protocol 
(p = 0.840) (Table 4).
Seven studies using FSH alone vs. FSH + hCG were compared, 
for a total of 948 patients. The overall analysis did not find sig-
nificant differences in the number of oocytes retrieved between 
groups (p = 0.850) (Figure 2B; Table 4).
Twenty studies compared hMG with FSH for COS, for a total 
of 5,512 patients. Number of oocytes retrieved was significantly 
higher in FSH than hMG group (p < 0.001) (Figure 2C; Table 4). 
Four of these studies used a GnRH antagonist protocol, confirming 
the significant increase of oocytes retrieved (p < 0.001), but no 
difference was found in the 16 studies using GnRH agonist pro-
tocol (p = 0.110) (Table 4).
Finally, 5 studies evaluated the oocytes number compar-
ing FSH plus LH to FSH plus hCG, for a total of 538 women. 
The analysis did not find significant difference between groups 
(p = 0.530) (Table 4).
Fsh Dose/retrieved Oocyte ratio
The FSH/retrieved oocyte ratio was significantly lower when LH 
was added to FSH (p < 0.001) (Table 4), as evaluated in 26 studies 
FigUre 2 | Forrest plot evaluating the retrieved oocytes number comparing follicle-stimulating hormone alone to luteinizing hormone (a), human 
chorionic gonadotropin (B), and human menopausal gonadotropin (c).
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for a total of 5,404 women enrolled. However, different results 
were found considering the protocol of COS used. In particular, 
no significant difference was observed in GnRH agonist protocol 
(p = 0.080) (Table 4). On the contrary, a lower ratio was obtained 
when LH was added to FSH in the GnRH antagonist protocol 
(p < 0.001) (Table 4).
On the other hand, 6 studies compared the use of FSH alone 
with FSH plus hCG, for a total of 893 patients. The overall analysis 
did not find significant differences in the ratio between FSH dose 
and oocytes retrieved between groups (p = 0.550) (Table 4).
Fifteen studies compared hMG with FSH for COS, for a total 
of 4,436 patients. The ratio between FSH dose and the number of 
oocytes retrieved was significantly lower in the FSH compared to 
hMG group (p < 0.001) (Table 4). This significant difference was 
lost in the 12 studies using a GnRH agonist protocol (p = 0.090), 
while remained in the three studies using a GnRH antagonist 
protocol (p < 0.001) (Table 4).
Finally, 4 studies evaluated the ratio comparing FSH plus 
LH to FSH plus hCG, for a total of 382 women. No differences 
in the FSH/retrieved oocyte ratio were found between groups 
(p = 0.480) (Table 4).
Mii Oocytes
Twenty studies reported the MII oocytes number, comparing 
FSH alone and FSH + LH. The two groups did not differ con-
sidering the mean MII oocytes number (p = 0.050), even when 
GnRH agonist or antagonist protocols were considered separately 
(p = 0.050 and p = 0.540, respectively) (Table 4).
Five studies compared FSH alone vs. FSH +  hCG, without 
finding differences in the mean MII oocytes number (p = 0.730) 
(Table 4).
Eleven studies compared FSH vs. hMG, finding no differences 
in the mean difference of MII oocytes (p =  0.100) (Table  4). 
Although this result remained also considering GnRH agonist 
protocols (p = 0.840), the MII oocytes number was significantly 
higher when FSH was used rather than hMG (p < 0.001) (Table 4).
Four studies compared directly FSH + LH vs. FSH + hMG, 
finding no difference in the MII oocytes number (p =  0.070) 
(Table 4).
embryos
Twenty-six studies reported the embryo number in the com-
parison between FSH alone vs. FSH +  LH, without significant 
differences (p = 0.540) (Table 4). Similarly, no differences were 
observed in the GnRH agonist (p = 0.430) and antagonist group 
(p = 0.640).
Seven studies demonstrated a similar embryo number in the 
comparison of FSH alone vs. FSH + hCG (p = 0.770) (Table 4).
Sixteen studies described the embryo number in the com-
parison between FSH and hMG. In this subgroup, hMG showed 
a higher embryo number (p = 0.001), maintained when GnRH 
agonist was used (p <  0.001), but not in the GnRH antagonist 
group (p = 0.860) (Table 4).
The direct comparison between FSH + LH and FSH + hMG 
demonstrated a higher embryo number when FSH was used 
combined to LH (p < 0.001) (Table 4).
TaBle 4 | Main results of meta-analyses subgroups.
luteinizing hormone  
(lh) + follicle-stimulating  
hormone (Fsh) vs. Fsh
human chorionic  
gonadotropin  
(hcg) + Fsh vs. Fsh
human menopausal  
gonadotropin  
(hMg) vs. Fsh
lh + Fsh vs. 
hcg + Fsh
OOcYTes reTrieVeD (Mean DiFFerence)
Overall analysis −0.20 (−0.36, −0.04) 0.24 (−2.27, 2.75) −0.92 (−1.45, −0.39) 0.39 (−0.83, 1.61)
p = 0.01 p = 0.850 p < 0.001 p = 0.530
I2 = 88% I2 = 99% I2 = 94% I2 = 96%
29 studies 7 studies 20 studies 5 studies
5,840 patients 948 patients 5,512 patients 538 patients
Gonadotropin-releasing  
hormone (GnRH) agonist
−0.35 (−0.63, −0.08) – −0.43 (−0.95, 0.10) –
p = 0.01 p = 0.11
I2 = 93% I2 = 93%
17 studies 16 studies
3,677 patients 3,347 patients
GnRH antagonist 0.01 (−0.13, 0.16) – −2.38 (−3.10, −1.66) –
p = 0.840 p < 0.001
I2 = 54% I2 = 42%
10 studies 4 studies  
2,163 patients 2,165 patients
Fsh/OOcYTes (Mean DiFFerence)
Overall analysis −0.16 (−0.21, −0.11) −0.04 (−0.17, 0.09) 0.17 (0.11, 0.23) −0.25 (−0.94, 0.44)
p < 0.001 p = 0.550 p < 0.001 p = 0.480
I2 = 92% I2 = 84% I2 = 86% I2 = 90%
26 studies 6 studies 15 studies 4 studies
5,404 patients 893 patients 4,436 patients 382 patients
GnRH agonist −0.06 (−0.13, 0.01) – 0.07 (−0.01, 0.14) –
p = 0.080 p = 0.090
I2 = 90% I2 = 84%
18 studies 12 studies
3,613 patients 2,900 patients
GnRH antagonist −0.36 (−0.45, −0.26) – 0.35 (0.25, 0.45) –
p < 0.001  p < 0.001
I2 = 95% I2 = 74%
8 studies 3 studies
1,791 patients 1,536 patients
Mii OOcYTes (Mean DiFFerence)
Overall analysis −0.27 (−0.56, 0.02) −0.37 (−2.45, 1.71) −0.60 (−1.31, 0.12) −0.54 (−1.13, 0.05)
p = 0.07 p = 0.730 p = 0.10 p = 0.07
I2 = 94% I2 = 91% I2 = 89% I2 = 92%
20 studies 5 studies 11 studies 4 studies
3,544 patients 352 patients 2,871 patients 424 patients
GnRH agonist −0.50 (−1.01, 0.01) – 0.15 (−1.30, 1.60) –
p = 0.05 p = 0.84
I2 = 96% I2 = 86%
13 studies 7 studies
1,915 patients 706 patients
GnRH antagonist 0.04 (−0.08, 0.15) – −1.36 (−1.51, −1.21) –
p = 0.54 p < 0.001
I2 = 17% I2 = 0%
7 studies 4 studies
1,629 patients 2,165 patients
eMBrYOs (Mean DiFFerence)
Overall analysis −0.04 (−0.17, 0.10) 0.07 (−0.39, 0.53) 0.19 (0.07, 0.30) −0.12 (−0.19, −0.06)
p = 0.54 p = 0.77 p = 0.001 p < 0.001
I2 = 83% I2 = 74% I2 = 94% I2 = 83%
26 studies 7 studies 16 studies 4 studies
4,721 patients 918 patients 3,321 patients 500 patients
(Continued)
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luteinizing hormone  
(lh) + follicle-stimulating  
hormone (Fsh) vs. Fsh
human chorionic  
gonadotropin  
(hcg) + Fsh vs. Fsh
human menopausal  
gonadotropin  
(hMg) vs. Fsh
lh + Fsh vs. 
hcg + Fsh
GnRH agonist −0.07 (−0.25, 0.11) – 0.23 (0.10, 0.35) –
p = 0.43 p < 0.001
I2 = 88% I2 = 95%
17 studies 13 studies
2,890 patients 2,589 patients
GnRH antagonist 0.03 (−0.11, 0.18) – −0.02 (−0.19, 0.16) –
p = 0.64 p = 0.86
I2 = 36% I2 = 74%
9 studies 3 studies
1,831 patients 732 patients
iMPlanTaTiOn raTe (Mean DiFFerence)
Overall analysis 0.11 (0.00, 0.21) −0.06 (−0.03, 0.01) 0.22 (0.02, 0.23) −0.00 (−0.16, 0.15)
p = 0.05 p = 0.59 p = 0.03 p = 0.98
I2 = 99% I2 = 0% I2 = 100% I2 = 96%
15 studies 5 studies 10 studies 4 studies
2,669 patients 749 patients 3,208 patients 430 patients
GnRH agonist 0.16 (0.00, 0.31) – 0.25 (−0.01, 0.51) –
p = 0.05 p = 0.06
I2 = 100% I2 = 100%
10 studies 8 studies
1,256 patients 2,299 patients
GnRH antagonist 0.01 (−0.08, 0.10) – 0.15 (0.13, 0.17) –
p = 0.83 p < 0.001
I2 = 85% I2 = 0%
6 studies 2 studies
1,393 patients 909 patients
PregnancY raTe (ODDs raTiO)
Overall analysis 1.20 (1.06, 1.37) 0.96 (0.72, 1.26) 1.10 (0.98, 1.22) 1.73 (1.26, 2.38)
p = 0.004 p = 0.750 p = 0.100 p < 0.001
I2 = 5% I2 = 0% I2 = 0% I2 = 48%
29 studies 8 studies 25 studies 5 studies
5,665 patients 968 patients 6,894 patients 989 patients
GnRH agonist 1.27 (1.09, 1.48) – 1.17 (1.01, 1.36) –
p = 0.002 p = 0.030
I2 = 9% I2 = 0%
22 studies 17 studies
3,834 patients 3,627 patients
GnRH antagonist 1.08 (0.87, 1.35) – 1.10 (0.90, 1.34) –
p = 0.480 p = 0.370
I2 = 0% I2 = 0%
9 studies 4 studies
1,831 patients 2,165 patients
liVe BirTh raTe (ODDs raTiO)
Overall analysis 1.29 (0.91, 1.84) – 1.13 (0.95, 1.33) –
p = 0.15 p = 0.17
I2 = 45% I2 = 10%
5 studies – 7 studies –
164 patients 747 patients
Bold character indicates significant results.
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implantation rate
The implantation rate was calculated as the ratio between number 
of gestational sacs and the number of transferred embryos. This 
was reported in 15 studies comparing FSH alone vs. FSH + LH, 
demonstrating a similar rate (p = 0.050), maintained both in GnRH 
agonist (p = 0.050) and antagonist protocols (p = 0.830) (Table 4).
Five studies demonstrated an equal implantation rate in the 
comparison FSH alone vs. FSH + hCG (p = 0.590) (Table 4).
FigUre 3 | continued
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Ten studies showed a higher implantation rate when hMG was 
used instead of FSH (p = 0.030) (Table 4). This result remained 
in the GnRH antagonist group (p < 0.001), but not in the GnRH 
agonist group (p = 0.060) (Table 4).
No different implantation rate was found when FSH + LH was 
directly compared to FSH + hMG (p = 0.980) (Table 4).
Pregnancy rate
The pregnancy rate was significantly higher when LH was added 
to FSH (p = 0.004), as evaluated in 29 studies for a total of 5,565 
women enrolled (Figure 3A; Table 4).
Similarly, the higher pregnancy rate for the FSH plus LH group 
was maintained only when a GnRH agonist was used (p = 0.002), 
not with GnRH antagonist (p = 0.480) (Table 4).
Eight studies compared the use of FSH alone vs. FSH + hCG, 
for a total of 968 patients. The overall analysis did not find sig-
nificant differences in pregnancy rate between groups (p = 0.750) 
(Figure 3B; Table 4).
Twenty-five studies compared hMG vs. FSH during COS, for 
a total of 6,894 patients. Pregnancy rate did not differ between 
groups (p =  0.100) (Figure  3C; Table  4). However, pregnancy 
rate was significantly higher when hMG was used in a GnRH 
agonist protocol (p = 0.030), while it did not change in a GnRH 
FigUre 3 | Forrest plot evaluating the pregnancy rate comparing follicle-stimulating hormone alone to luteinizing hormone (a), human chorionic 
gonadotropin (B), and human menopausal gonadotropin (c).
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antagonist regimen (p =  0.370) (Table  4). In the comparison 
between hMG vs. FSH alone, considering only IVF/ICSI cycles, 
22 studies remained in the analysis, for a total of 6,354 patients. 
Pregnancy rate did not differ between groups (p = 0.070) (Figure 
S1 in Supplementary Material). Considering only GnRH agonist 
protocols, 18 studies remained in the analysis, confirming the 
improved pregnancy rate in hMG group vs. FSH alone (p = 0.003) 
(Figure S2 in Supplementary Material).
Finally, five studies evaluated pregnancy rate comparing 
FSH + LH vs. FSH + hCG, for a total of 989 women. A higher 
pregnancy rate was observed when LH was added to FSH, rather 
than hCG (p < 0.001) (Table 4).
live Birth rate
Five studies reported the live birth rate in the comparison of FSH 
alone vs. FSH + LH, without significant differences (p = 0.150) 
(Table 4). Similar result was obtained when FSH alone was com-
pared to FSH + hCG (8 studies, p = 0.750) and to hMG (7 studies, 
p = 0.170) (Table 4).
Meta-regression analyses
Considering each subgroup analysis, the number of oocytes 
retrieved was directly related to the cumulative FSH dose when 
FSH alone was used (R  =  0.342, p  =  0.002), instead of the 
combination FSH + LH (R = 0.146, p = 0.060). On the contrary, 
the cumulative FSH dose was not related to the oocytes number 
when FSH was compared to hMG (R = 0.022, p = 0.543).
risk-of-Bias
The risk-of-bias was evaluated and summarized in Figure 4.
Overall Model
The main concepts found by our data analysis were graphically 
summarized by a plot (Figure  5), representing the means and 
95% confidence intervals of each fertilization step and gonado-
tropin regimen as extensively detailed in the subchapters above. 
In this overall model, COS served as an example of gonadotropins 
efficacy in  vivo illustrating LH and hCG action on the ovary 
(Figure  5). Second-order polynomial functions were used as a 
fitting model of the standard mean differences (on the Y axis) 
calculated for each endpoint of the meta-analysis, considering 
FSH + LH vs. FSH alone, FSH + hCG vs. FSH alone and hMG vs. 
FSH (Figure 5). The number of oocytes retrieved is higher when 
FSH is used alone in all comparison, but the addition of LH or 
LH activity (such as in the case of hMG) progressively improves 
the ART outcomes, suggesting a positive effect of LH on oocyte 
quality. Especially, MII oocytes, embryos, implantation rate, and 
pregnancy rate improve progressively and linearly when LH is 
FigUre 5 | Overall model of meta-analysis results. Each scatter plot represents the mean differences with related confidence interval (95%) for each of assisted 
reproductive technology outcomes evaluated. The three lines represent the polynomial trend line. Red line shows the results with luteinizing hormone 
supplementation, blue line with human menopausal gonadotropin and black line with human chorionic gonadotropin.
FigUre 4 | risk-of-bias graph: the authors’ judgment about each risk-of-bias item is presented as percentages across all included studies.
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used (red line), an effect attenuated when hMG is used (blue line) 
(Figure 5). On the contrary, hCG addition does not improve ART 
outcome (black line) (Figure 5).
DiscUssiOn
This is the first meta-analysis comparing comprehensively 
the efficacy of the mostly used gonadotropin combinations in 
ART. We find that the administration of FSH alone during COS 
retrieves higher oocyte number than either LH supplementation 
or hMG use. However, the combined use of FSH + LH reduces 
the FSH dose required for oocyte retrieved, while hMG leads to 
higher FSH dose needed. Interestingly, FSH + LH increases the 
pregnancy rate of about 1.20 fold, in spite of lower number of 
oocyte retrieved compared to FSH alone, whereas hMG does 
not. On the contrary, FSH + hCG treatment does neither change 
final oocytes number, nor FSH dose required for each oocyte, nor 
pregnancy rate. Although live birth rate is usually considered a 
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better endpoint than pregnancy rate to evaluate ART outcome, it 
is not reported in many studies included and our meta-analysis 
does not show significant difference in live birth rate. All these 
differences are modest but, although apparently not clinically 
relevant, they are useful to better understand in vivo the overall 
effects of the different gonadotropin regimens.
These results suggest that gonadotropin preparations dif-
ferently influence COS outcome, providing some evidence for 
ART personalization and improvement and leading to different 
results compared to those of previous meta-analyses. This differ-
ence could be due to the wide range of studies evaluated, which 
are focused on different endpoints and patient characteristics. 
FSH +  LH treatment is linked to a relatively lower number of 
oocytes retrieved but higher pregnancy rate. The addition of LH 
or LH-activity might increase the selective pressure exerted on 
follicular selection exerted by the two gonadotropins together, 
compensated by improved oocyte quality. Indeed, the differences 
between FSH alone and FSH + LH or LH activity are lost, at least 
in terms of MII oocyte number. Moreover, the use of hMG leads 
to a higher embryos number and implantation rate compared to 
FSH alone. These results confirmed that the higher pregnancy 
rate found when FSH + LH or hMG are used together with GnRH 
agonist protocol, instead of FSH alone, is due to a positive effect 
of better oocyte quality on fertilization and embryo implantation. 
On the contrary, FSH + hCG treatment does not change ART 
outcomes compared to FSH alone, suggesting that LH and hCG 
result in different actions in vivo in the presence of FSH, reflecting 
in vitro observations (3). The overall model (Figure 5) shows a 
progressively better outcome when FSH is used together with LH 
or LH-activity (such as hMG). Thus, LH and hCG action in vivo is 
different in women undergoing COS, with LH improving oocyte 
maturation and quality, and therefore pregnancy rate, more than 
hCG, reflecting previous in vitro data.
Luteinizing hormone and hCG are characterized by specific 
molecular and biochemical features; they interact with distinct 
binding sites of the same receptor (25–27), resulting in lower 
dissociation rate by hCG than LH binding (28). Gonadotropin-
specific ligand-receptor features imply different gene expression 
and intracellular signaling in vitro, whereby LH triggers higher 
levels of ERK1/2- and AKT-pathway activation than hCG, which, 
in turn, mediates more potent cAMP increase in human primary 
granulosa cells (2). Downstream effects of gonadotropins’ signal-
ing consist in LH-related proliferative and anti-apoptotic signals, 
vs. high steroidogenic potential and pro-apoptotic activity of hCG 
in vitro, in both human and goat primary granulosa cells (3, 29). 
In particular, cell death was described as a result of the intracel-
lular cross-talk among cAMP/protein kinase A (PKA)-mediated 
steroidogenic and pro-apoptotic pathways (30) preferentially 
activated by FSH and hCG, in steroidogenic cells in vitro (31).
Interestingly, our analysis of the literature reveals that LH addi-
tion to FSH treatment for ART provides lower oocyte numbers 
than other treatments, probably as a result of higher follicular 
selection (which is apoptosis-mediated). In this regard, few spec-
ulative considerations should be done. First, COS cycles are far 
from being a physiologic hormonal regimen; they are optimized 
for multi-follicular maturation in order to obtain the highest 
number of healthy oocytes (32), subjecting ovaries to treatments 
with pre-designed, high doses of exogenous hormones, which 
change the natural endocrine milieu of the woman. As a result, a 
mono-ovulatory species becomes multi-ovulatory, deviating from 
the natural, cyclic balance between gonadotropins and steroid 
hormones (33) and, thereby, life/death signals, a situation clearly 
different from ovarian physiology. On the other hand, FSH and 
LH are naturally produced to regulate mono-follicular selection, 
growth and maturation. The message provided by in vitro studies 
is that highly steroidogenic gonadotropins, i.e., FSH and hCG, 
mediate apoptotic stimuli in granulosa cells via cAMP/PKA-
pathway (2, 3, 29–31). In the ovarian setting of a multi-follicular 
maturation as in COS, stimulation is a potent signal for early 
tertiary follicle recruitment (34) and triggering steroidogenesis, 
results in estrogen over-production which, in turn, induces more 
pronounced multi-follicular survival and maturation (35) than 
that inducible by LH treatment.
The ART outcome obtained with hMG reflects the heterogene-
ity typical of this compound. hMG derives from post-menopausal 
or pregnant women and contains both FSH and LH activities 
(36). LH activity is provided by residual LH molecules and by 
hCG supplementation, leading to high variability of the product 
(37). Moreover, given the high steroidogenic potential of hCG 
demonstrated in  vitro (2, 31), which is more similar to that of 
FSH rather than LH (31), it is not surprising that ART outcome 
does not change whether hMG is used instead of FSH, except 
in GnRH agonist protocols, where high oocyte numbers might 
possibly occur as a positive effect of the flare-up phase on follicle 
recruitment. The discrepancy provided by GnRH-agonist and 
-antagonist protocols was not demonstrated by previous meta-
analyses, likely due to strict inclusion criteria focused specifically 
on the evaluation of the analog instead of gonadotropins combi-
nation. The most recent meta-analysis on this field suggests only 
a significant adverse events occurrence reduction when GnRH 
antagonists are used (38).
This study suggests that GnRH antagonist protocol may be 
disadvantageous for oocytes quality, although the addition of LH 
seems to compensate, at least in part, this negative effect. FSH 
alone allows higher number of oocytes retrieved than FSH + LH, 
in GnRH agonist, but not antagonist protocols. GnRH antagonist 
is linked to lower FSH doses required for each oocyte retrieved, in 
the presence of LH. Moreover, pregnancy rate is higher by hMG 
than FSH treatment in GnRH agonist, but not antagonist proto-
cols. This reflects the different mechanism of action and possibly 
different effects among GnRH analogs, which was hypothesized, 
although largely debated (39). GnRH analogs are differently used 
in clinical practice. In particular, GnRH agonists are generally 
proposed in women with BMI <25 kg/m2 (40), in poor respond-
ers (38, 41), and/or as a final trigger to minimize the ovarian 
hyperstimulation syndrome (OHSS) occurrence (42). Overall, 
GnRH antagonist is linked to reduced COS duration and overall 
medical costs of the stimulation phase and is recommended 
when a mild stimulation is required, such as for hyper-responder 
women (38, 43) or PCOS patients (44). These results support the 
hypothetical difference between agonists and antagonists, which 
was never demonstrated by previous meta-analyses (Table 1).
With this in mind, the cost-effectiveness evaluation currently 
remains the main variable useful to guide the clinician choice in the 
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setting of the personalized therapy (45). However, the assessment 
of ART costs is particularly challenging, and the consideration 
of both COS-related and pregnancy/infant-associated medical 
costs is mandatory. Several studies evaluated the ART medical 
costs alone, considering the cumulative gonadotropin dosages 
used, the cycle cancelation rate and the risk of adverse events. The 
FASTT study suggested that IUI was the cheapest/efficient first-
line treatment (46), while the FORT-T trial suggested better cost-
effectiveness results when sequential traditional embryo transfer 
is selected (47). Crawford et al. (48) recently evaluated the overall 
ART costs in 14,398 cycles, suggesting that sequential embryo 
transfer is more expensive, concerning the procedure costs, but 
markedly cheaper overall, reducing multiple live births and total, 
final expenses. Although each study seems to be conclusive, these 
results remain challenging, and international or national consen-
sus on the best COS approach is not reached so far. Moreover, 
the gonadotropin combination is not generally considered in this 
cost-effectiveness evaluation, limiting the strength of these sug-
gestions. Our results suggest a reduced FSH dose needed for each 
oocyte retrieved when the combination of FSH + LH was used for 
COS. Thus, the gonadotropin combination should be considered 
in the cost-saving evaluation of a specific ART procedure. The 
overall charge, even when LH, hCG, or hMG are used in addition/
substitution to FSH, must be considered according to the local 
reimbursement system. Finally, no study so far evaluated the 
“weight” of gonadotropin-producing companies on the clinician’s 
decision.
The main limit of this meta-analysis is the heterogeneity of 
studies included as suggested by the elevated I2 score. Couple 
infertility represents a challenging clinical condition, difficult 
to define according to strict clinical criteria. Indeed, different 
inclusion and exclusion criteria are used in each trial, making 
the comprehensive comparison of these results difficult. As 
a confirmation, a recent phase III single-blind, randomized, 
parallel-group clinical trial performed on 939 poor responder 
women did not find any safety and efficacy differences between 
FSH alone and FSH + LH (49). This reinforces the knowledge of 
a high heterogeneity of studies in ART setting, in which also the 
women classification as poor responders could mask the different 
gonadotropin effects in vivo. The relative high risk-of-bias of the 
studies included, as shown in Figure 4, represents an important 
limit that should be carefully considered to design further appro-
priate studies. However, although the pharmacological approach 
to ART is evaluated, no publication biases are evident at funnel 
plots analyses (data not shown). As highlighted by previous 
meta-analyses, we found high selection and allocation biases, 
confirming the finding that more than 80% of clinical trials did 
not apply any blinding technique (50). This high percentage is 
probably due to the difficulty in applying these procedures to 
ART, in which over 30 therapeutic complex approaches are cur-
rently available.
In conclusion, we found that different performance in ART 
is depending on gonadotropin combination used for COS, 
reflecting the physiological role of these molecules as previously 
indicated by in vitro data. This leads to important implication for 
clinical practice, where pregnancy rate or oocyte numbers might 
be the preferentially selected outcome. Especially, LH addition 
to FSH decreases FSH need and progressively improves ART 
outcomes and pregnancy rate. In GnRH agonist protocols, a bet-
ter pregnancy rate is obtained by FSH + LH and hMG treatment. 
FSH + hCG or hMG alone are equally effective compared to FSH 
alone on pregnancy rate.
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